Table 3.

Select Trials of Established FLT3 inhibitors in R/R AML.

NCT/Trial Identifier	Phase	Treatment Setting	Patient Population
Quizartinib
NCT03989713/Q-HAM	II	Combination with salvage chemotherapy (Ara-C, Mitoxantrone); R/R after first-line treatment, including HCT	FLT3-ITD AML; age 18−75
NCT04047641	II	Combination with cladribine, idarubicin, and cytarabine; any previous treatment	All AML, MDS; age ≥ 18 (R/R cohort)
NCT04209725	II	Combination with liposomal cytarabine and anthracycline (CPX-351; Vyxeos); R/R after any prior treatment, first-line treatment must have been standard induction chemotherapy	FLT3-ITD AML; age 18−75
NCT04128748	I/II	Combination with liposomal cytarabine and anthracycline (CPX-351; Vyxeos); R/R to first, second, third, or fourth line therapy	All AML, MDS; age ≥ 18
NCT04112589	I/II	Combination with FLAG-Ida (fludarabine, cytarabine, idarubicin, GCSF); R/R to frontline standard induction chemotherapy	All AML; age 18−70
Crenolanib
NCT03250338	III	Crenolanib vs Placebo plus salvage chemotherapy; R/R after first or second-line treatment, including HCT	FLT3-ITD and -D835; age 18−75